key: cord-0833821-l6gyryvd
authors: Tada, Takuya; Fan, Chen; Chen, Jennifer S.; Kaur, Ramanjit; Stapleford, Kenneth A.; Gristick, Harry; Dcosta, Belinda M.; Wilen, Craig B.; Nimigean, Crina M.; Landau, Nathaniel R.
title: A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2
date: 2020-12-01
journal: Cell Rep
DOI: 10.1016/j.celrep.2020.108528
sha: 91ec2e6f751b806d89b69a8e2171d63c96b31372
doc_id: 833821
cord_uid: l6gyryvd

Soluble forms of ACE2 have recently been shown to inhibit SARS-CoV-2 infection. We report on an improved soluble ACE2, termed a “microbody” in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain. The protein is smaller than previously described ACE2-Ig Fc fusion proteins and contains an H345A mutation in the ACE2 catalytic active site that inactivates the enzyme without reducing its affinity for the SARS-CoV-2 spike. The disulfide-bonded ACE2 microbody protein inhibits entry of SARS-CoV-2 spike protein pseudotyped virus and replication of live SARS-CoV-2 in vitro and in a mouse model. Its potency is 10-fold higher than soluble ACE2 and it can act after virus bound to the cell. The microbody inhibits the entry of β coronaviruses and virus with the variant D614G spike. The ACE2 microbody may be a valuable therapeutic for COVID-19 that is active against viral variants and future coronaviruses.

Soluble forms of ACE2 have recently been shown to inhibit SARS-CoV-2 infection. We report on an improved soluble ACE2, termed a "microbody" in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain. The protein is smaller than previously described ACE2-Ig Fc fusion proteins and contains an H345A mutation in the ACE2 catalytic active site that inactivates the enzyme without reducing its affinity for the SARS-CoV-2 spike. The disulfide-bonded ACE2 microbody protein inhibits entry of SARS-CoV-2 spike protein pseudotyped virus and replication of live SARS-CoV-2 in vitro and in a mouse model. Its potency is 10-fold higher than soluble ACE2 and it can act after virus bound to the cell. The microbody inhibits the entry of β coronaviruses and virus with the variant D614G spike. The ACE2 microbody may be a valuable therapeutic for COVID-19 that is active against viral variants and future coronaviruses.

J o u r n a l P r e -p r o o f Introduction (Belouzard et al., 2012; Fehr and Perlman, 2015; Heald-Sargent and Gallagher, 2012; Li et al., 2006; Shang et al., 2020) . Cells that express ACE2 are potential targets of the virus. These include cells in the lungs, arteries, heart, kidney, and intestines (Harmer et al., 2002; Ksiazek et al., 2003; Leung et al., 2003) .

The use of soluble receptors to prevent virus entry by competitively binding to viral envelope glycoproteins was first explored for HIV-1 with soluble CD4. In early studies, a soluble form of CD4 deleted for the transmembrane and cytoplasmic domains was found to block virus entry in vitro (Daar et al., 1990; Haim et al., 2009; Orloff et al., 1993; Schenten et al., 1999; Sullivan et al., 1998) . Fusion of the protein to an immunoglobulin Fc region, termed an "immunoadhesin", increased the avidity for gp120 by dimerizing the protein and served to increase the half-life of the protein in vivo. An enhanced soluble CD4-Ig containing a peptide derived from the HIV-1 coreceptor CCR5 was found to potently block infection and to protect rhesus macaques from infection (Chiang et al., 2012) . The soluble receptor approach to blocking virus entry has been recently applied to SARS-CoV-2 through the use of recombinant human soluble ACE2 protein (hrsACE2) (Kuba et al., 2005; Monteil et al., 2020; Wysocki et al., 2010) or hrsACE2-IgG which encodes soluble ACE2 and the Fc region of the human immunoglobulin G (IgG) (Case et al., 2020; Lei et al., 2020; Qian and Hu, 2020) which were shown to inhibit of SARS-CoV and SARS-CoV-2 entry in a mouse model. In phase 1 and phase 2 clinical trials (Haschke et al., 2013; Khan et al., 2017) , the protein showed partial antiviral activity but short half-live. Addition of the Fc region increased the half-life of the protein in vivo. A potential concern with the addition of the Ig Fc region is the possibility of enhancement, J o u r n a l P r e -p r o o f similar to what occurs with antibody-dependent enhancement in which anti-spike protein antibody attaches to Fc receptors on immune cells, facilitating infection rather than preventing it (Eroshenko et al., 2020) .

We report, here on a soluble human ACE2 "microbody" in which the ACE2 ectodomain is fused to domain 3 of immunoglobulin G heavy chain Fc region (IgG-CH3) (Maute et al., 2015) . The IgG-CH3 Fc domain served to dimerize the protein, increasing its affinity for the SARS-CoV-2 S and decreased the molecular mass of the protein as compared to fusion with full-length Fc. The ACE2 microbody did not bind to cell surface Fc receptor, reducing any possibility of infection enhancement. Mutation of the active site H345 to alanine in the ACE2 microbody protein, a mutation that has been shown to inactivate ACE2 catalytic activity (Guy et al., 2005) , did not decrease its affinity for the spike protein. The dimeric ACE2 microbody had about 10-fold higher antiviral activity than soluble ACE2, which was also a dimer, and high a higher affinity for virion binding. The ACE2 microbody blocked virus entry into ACE2.293T cells that over-expressed ACE2 as well as all of the cell lines tested. It was active against the D614G variant spike protein and against a panel of β coronavirus spike proteins and protected human ACE2 transgenic mice against infection.

Results SARS-CoV-2 ∆19 spike protein was incorporated in pseudotyped virion and had higher infectivity.

As a means to study SARS-CoV-2 entry, we developed an assay based on SARS-CoV-2 spike protein pseudotyped lentiviral reporter viruses. The viruses package a lentiviral vector genome that encodes nanoluciferase and GFP separated by a P2A self-processing peptide, providing a convenient means to titer the virus, and the ability to use two different assays to measure infection. To pseudotype the virions, we constructed expression vectors for the full-length SARS-CoV-2 S and for a ∆19 variant, deleted for the carboxy-terminal 19 amino acids that removes a reported endoplasmic reticulum retention sequence that blocks transit of the spike protein to the cell surface (Giroglou et al., 2004) (Figure 1A) . The vectors were constructed with or without a carboxy-terminal hemagglutinin (HA) epitope tag. Pseudotyped viruses were produced in 293T cells cotransfected with the dual nanoluciferase/GFP reporter lentiviral vector pLenti.GFP.NLuc, Gag/Pol expression vector pMDL and full-length spike protein, the ∆19 spike protein, vesicular stomatitis virus G protein (VSV-G) expression vector or without an envelope glycoprotein expression vector. Immunoblot analysis showed that full-length and ∆19 spike proteins were expressed and processed into the cleaved S2 protein (S1 is not visible as it lacks an epitope tag). Analysis of the virions showed that the ∆19 spike protein was packaged into virions at >20-fold higher levels than the full-length protein ( Figure 1B) . This difference was not the result of differences in virion J o u r n a l P r e -p r o o f production as similar amounts of virion p24 capsid protein were present in the cell supernatant. Analysis of the transfected 293T cells by flow cytometry showed a minor increase in the amount of cell surface ∆19 spike protein as compared to full-length ( Figure 1C ) suggesting that deletion of the endoplasmic reticulum retention signal was not the primary cause of the increased virion packaging of the ∆19 spike protein and may result from an inhibitory effect of the spike protein cytoplasmic tail on virion incorporation.

As a suitable target cell line, we established a clonal, stably transfected 293T cell line that expressed high levels of ACE2 (Figures 1D and S1) . A comparison of the infectivity of the viruses on ACE2.293T cells showed that the ∆19 spike protein pseudotype was about 2.5-fold more infectious than the full-length spike protein pseudotype ( Figure 1E ).

The HA-tag had no effect on infectivity and the nevirapine control demonstrated that the luciferase activity was the result of bona fide infection and not carried-over luciferase in the virus-containing supernatant.

To determine the cell-type tropism of the pseudotyped virus, we tested several standard laboratory cell lines for susceptibility to infection to the ∆19 spike protein pseudotyped virus. The VSV-G pseudotype, which has very high infectivity on most cell-types was tested for comparison and virus lacking a glycoprotein was included to control for potential receptor-independent virus uptake. The results showed high infectivity of the ∆19 spike protein pseudotyped virus on ACE2.293T cells, intermediate infectivity on 293T, Vero, Vero E6, A549, ACE2.A549, CaCO2 and Huh7 and low infectivity on A549, CHME3 and BHK. (Figure 1F ). Vero and Vero E6 are African Green Monkey cells and as such express TRIM5α which likely accounts for the slight decrease J o u r n a l P r e -p r o o f in infectability of these cells by the VSV-G control pseudotype virus (Carthagena et al., 2008; Nakayama and Shioda, 2010; Stremlau et al., 2004) . Flow cytometry analysis for ACE2 showed high level expression on ACE2.293T, intermediate level on ACE2.A549 and a low to undetectable level on Vero, Vero E6, A549, CaCO2 and Huh7 ( Figure S1 ).

The absence of detectable ACE2 on these cell lines suggests either that virus can use very small amounts of the receptor for entry or that there is an alternative receptor. To test this hypothesis, we pre-treated the cells with a blocking anti-ACE2 antibody prior to infection. The antibody largely blocked infection of ACE2.293T but had no effect on infection of Vero and the other cell lines suggesting the presence of an alternative receptor ( Figure 1G ).

Soluble ACE2 and ACE2-Fc fusions have been shown to inhibit SARS-CoV-2 infection (Case et al., 2020; Kuba et al., 2010; Lei et al., 2020; Monteil et al., 2020; Qian and Hu, 2020; Wysocki et al., 2010) . To increase the effectiveness of soluble ACE2 and improve therapeutic potential, we generated an ACE2-"microbody" in which the ACE2 ectodomain was fused to a single IgG CH3 domain of the IgG Fc region (Figure 2A ). This domain contains the disulfide bonding cysteine residues of the IgG Fc that are required to dimerize the protein, which would serve to increase the ACE2 microbody avidity for ACE2. To prevent potential unwanted effects of the protein on blood pressure due to the catalytic activity of ACE2, we mutated H345, one of the key active site histidine residues of ACE2, to alanine, a mutation that has been shown to block catalytic activity (Guy et J o u r n a l P r e -p r o o f al., 2005) . H345 lies underneath the spike protein interaction site so was predicted not to interfere with spike protein binding ( Figure 2B ). For comparison, we constructed vector encoding soluble ACE2 without the IgG CH3. The proteins were purified from transfected 293T cells and purified to homogeneity by Ni-NTA agarose affinity chromatography followed by size exclusion chromatography ( Figure S2 ). The oligomerization state of the proteins was analyzed by SDS-PAGE under nonreducing and reducing conditions. Under reducing conditions, the ACE2 and ACE2.H345A microbody proteins and soluble ACE2 ran at the 130 kDa and 120 kDa, consistent with their calculated molecular mass ( Figures 2C and S2) . Under nonreducing conditions, the ACE2 microbody and ACE2.H345A microbody proteins ran at 250 kDa, consistent with dimers while the soluble ACE2 ran as a monomer with a mass of 120 kDa ( Figure 2C) . Analysis of the proteins by size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) under nondenaturing conditions showed all three proteins to have a molecular mass consistent with dimers ( Figure 2D ). The mass of the ACE2 and ACE2.H345A microbody proteins was 218 kDa and 230 kDa, respectively, while soluble ACE2 was 180 kDa. Taken together, the results suggest that the ACE2 microbody proteins are disulfide-bonded dimers while soluble ACE2 is a nondisulfide-bonded dimer.

To compare the relative ability of the soluble ACE2 proteins to virions that display the spike protein, we established a virion pull-down assay. Ni-NTA beads were incubated with a serial dilution of the carboxy-terminal His-tagged soluble ACE2 proteins. Free spike J o u r n a l P r e -p r o o f protein was removed and the beads were then incubated with a fixed amount of lentiviral pseudotyped virions. Free virions were removed and the bound virions were quantified by immunoblot analysis for virion p24 capsid protein. To confirm that virus binding to the beads was specific for the bead-bound ACE2, control virions lacking the spike were tested. The results showed that spike protein pseudotyped virions bound to the beads while virions that lacked the spike protein failed to bind, confirming that the binding was specific ( Figure 3A ). In addition, a high titer human serum from a recovered individual blocked binding of the virions to the bead-bound ACE2 microbody ( Figure S5 ). Analysis of the soluble ACE2 and ACE2 microbody proteins that had bound to the beads showed that similar amounts of each proteins had bound ( Figure 3B ). Immunoblot analysis of virion binding to the bead-bound soluble ACE2 proteins showed that the wild-type and H345A microbody proteins both bound to virions more efficiently than soluble ACE2 ( Figure 3C ) and that the ACE2.H345A microbody bound more virions than the wild-type microbody protein. This was unexpected as H345 does not lie in the interaction surface with the spike protein.

To determine the relative antiviral activity of soluble ACE2 and the ACE2 microbody proteins, we tested their ability to block the infection SARS-CoV-2 ∆19 spike protein pseudotyped GFP/luciferase reporter virus. A fixed amount of pseudotyped reporter virus was incubated with the ACE2 proteins and then used to infect ACE2.293T cells.

After 2 days, luciferase activity and the number of GFP+ cells in the infected cultures J o u r n a l P r e -p r o o f were analyzed. For comparison, a high titered recovered patient serum with a neutralizing titer of 1:330 (figure S5) was also tested. The results showed that soluble ACE2 had moderate inhibitory activity with an EC 50 of 1.24 µg/ml. The ACE2 microbody was significantly more potent, with an EC 50 of 0.36 µg/ml and the ACE2.H345A microbody protein was somewhat more potent than the wild-type ACE2 microbody with an EC 50 of 0.15 µg/ml ( Figure 4A ). Inhibition of infection by the soluble ACE2 proteins was comparable to recovered patient serum although it is not possible to directly compare the two inhibitors as the mass amount of anti-spike protein antibody in the serum is not known. To confirm the results, we analyzed the infected cells by flow cytometry to determine the number of GFP+ cells. The inhibition curves were similar to the luciferase curves, confirming that the ACE2 proteins had decreased the number of cells infected and did not simply reduce expression of the reporter protein ( Figure 4B , top).

( Figure 4B , below). The inhibitory activity of the soluble ACE2 proteins was specific for the SARS-CoV-2 spike protein as they did not inhibit VSV-G pseudotyped virus ( Figure   4C ). The ACE2 microbody was somewhat more active when tested on untransfected 293T that express low levels of ACE2 ( Figure 4D ).

To determine the ability of the ACE2 microbody proteins to block the replication of live SARS-CoV-2, we used the replication-competent SARS-CoV-2, icSARS-CoV-2mNG that encodes an mNeonGreen reporter gene in ORF7 (Xie et al., 2020) . Serially diluted ACE2 microbody proteins were incubated with the virus and the mixture was then used to infect ACE2.293T cells. The results showed that 1-0.125 µg of ACE2 microbody J o u r n a l P r e -p r o o f protein blocked live virus replication ( Figure 4E ). Soluble ACE2 was less active; 1 µg of the protein had a 50% antiviral effect and the activity was lost with 0.5 µg. The antiviral activity of ACE2 proteins against live virus was similar to pseudotyped virus, except that in the live virus assay, the wild-type and H345A microbodies were of similar potency.

In the experiments described above, the proteins were incubated with virus prior to infection. To determine whether they would be active at later time points, the ACE2 proteins were tested in an "escape from inhibition" assay in which the soluble ACE2 and ACE2 microbody proteins were added to cells at the same time as virus or up to 6 hours post-infection. The results showed that addition of the microbody together with the virus (t 0 ) blocked the infection by 80%. Addition of the microbody 30 minutes post-infection maintained most of the antiviral effect, and even 2 hours post-infection the inhibitor blocked 55% of the infection. At 4 hours post-infection, the ACE2 microbody retained its blocking activity at 10 µg/ml but was less active with decreasing amounts of inhibitor ( Figure 5A ). These results suggest that the ACE2 microbody is highly efficient at neutralizing the virus when present before the virus has had a chance to bind to the cell and that it maintains its ability to block infection when added together with the cells and even 2 hours after the virus has been exposed to cells, a time which most of the virus

has not yet bound to the cell.

To determine whether the ACE2 microbody could prevent virus entry once the virus bound to the cell, the virus was prebound by incubating it with cells for 2 hours at 22°C, the unbound virus was removed and the ACE2 microbody was added at increasing time points. The results showed that removal of the unbound virus after 1 J o u r n a l P r e -p r o o f hour incubation resulted in less infection as compared to when the virus was incubated with the cells for 4 hours, indicating that only a fraction of the virus had bound to cells.

However, virus that was bound could be blocked by the ACE2 microbody for another 30 minutes post-binding ( Figure 5B ). The ability to block entry of the cell-bound virus suggests that virus binding results from a small number of spike molecules binding to ACE2. Over the next 30-60 minutes, additional spike protein:ACE2 interactions form, escaping the ability of the ACE2 microbody to block virus entry. The results demonstrate that the ACE2 microbody is a highly potent inhibitor of free virus and maintains its antiviral activity against virus newly-bound to the cell.

SARS-CoV-2 containing a D614G point mutation in the spike protein has been found to be circulating in the human population with increasing prevalence (Daniloski et al., 2020; Eaaswarkhanth et al., 2020; Korber et al., 2020) . The D614G mutation was found to decrease shedding of the spike protein from the virus and to assume a fusion-ready conformation, resulting in increased infectivity and most likely contributing to its increasing prevalence (Daniloski et al., 2020; Ozono et al., 2020; . To determine the ability of the soluble ACE2 proteins to block entry of virus with the D614G spike protein, we introduced the mutation into the ∆19 spike protein expression vector and generated pseudotyped reporter viruses ( Figure 6A) . Analysis of the infectivity of the D614G and wild-type pseudotyped viruses on the panel of cell lines showed that the mutation increased the infectivity of virus 2-4 fold on 293T, ACE2.293T, Vero and VeroE6 J o u r n a l P r e -p r o o f cells, consistent with previous reports (Daniloski et al., 2020; Ozono et al., 2020; . Infectivity of the mutated virus was also increased in A549, ACE2.A549

CaCO2 although the overall infectivity of these cells was low ( Figure 6B) . To determine the ability of the soluble ACE2 proteins to neutralize the virus with the variant spike protein, serial dilutions of the soluble ACE2 proteins were tested for their ability to block wild-type and D614G S pseudotyped virus. The results showed that soluble ACE2 had moderate antiviral activity against wild-type virus, while the wild-type and H345A microbody proteins were more potent ( Figure 6C ). The ACE2.H345A microbody was more active at low concentration than the wild-type protein. To test the relative binding affinities of the soluble ACE2 proteins for the wild-type and D614G spike proteins, we used an ACE2:virion binding assay in which the soluble ACE2 proteins were bound to nickel beads via their His-tag ( Figure 6D ). Different amounts of wild-type or D614G pseudotyped virions were then incubated with the beads and the amount of virions bound was quantified by immunoblot analysis. The results showed that the wild-type and H345A microbody proteins bound more efficiently than soluble ACE2 to the spike protein and that they bound well to both the wild-type and D614G spike protein-pseudotyped virions. features. The ACE2 microbody is fully of human origin so should be relatively non-immunogenic. In addition, the requirement that the spike protein maintain its affinity for ACE2 should make it difficult for the virus to evolve escape mutants despite its relatively high mutation rate, as decreased binding to the soluble receptor proteins would decrease viral fitness. The microbody was fully active against virus with the D614G spike protein, a variant of increasing prevalence with increased infectivity in vitro ( Figure 6B) and was highly active against ACE2-specific spike proteins from other β coronaviruses.

It has been shown that a recombinant ACE2-Fc fusion caused a marked decrease in blood pressure in a mouse model (Liu et al., 2018) . To prevent this unwanted effect in the ACE2 microbody proteins, we introduced an H345A mutation into the protein. The mutation changes one of the histidine residues in the active site that is essential for ACE2 carboxypeptidase activity without impairing its antiviral activity against SARS CoV-2 or other β coronavirus spike proteins. In some experiments, the ACE2.H345A microbody appeared to be more active than the wild-type protein although the significance of this difference was unclear as the two proteins had similar activity in the live virus replication assay. week (Liu et al., 2018) . The half-life of the ACE2 microbody in vivo has not yet been tested, but the protein retained antiviral activity for several days in tissue culture, significantly longer than longer than soluble ACE2 ( Figure S3 ). Fc γ receptor and the cells did not become infected, suggesting that this mechanism is not likely to play a role in vivo ( Figure S4 and not shown) .

laboratories as tools for titering neutralizing antibodies and testing entry inhibitors (Crawford et al., 2020; Nie et al., 2020; Ou et al., 2020; Schmidt et al., 2020; Shang et al., 2020; Xia et al., 2020) . The pseudotyped lentiviral vector system we developed here is highly effective. The high infectivity of the viruses produced is due, in part, to codon-optimization of the spike protein and to the cytoplasmic tail truncation. The ∆19 truncated spike protein was present at only slightly higher levels on the cell surface than the full-length protein, but was packaged 20-fold more efficiently. A possible explanation for the increased packaging efficiency is that the full-length cytoplasmic tail sterically hinders virion incorporation by conflicting with the underlying viral matrix protein. Also contributing to high viral titers, is the use of separate Gag/Pol packaging vector and lentiviral transfer vector as opposed to a lentiviral proviral DNA encoding Gag/Pol and the reporter gene, which we have found resulted in much higher viral titer (not shown).

The use of a dual nanoluciferase/GFP reporter in the system allows for measurement of infectious virus titer by flow cytometry and highly sensitivity nanoluciferase read-out. The results obtained using the lentiviral pseudotypes accurately reflect the results derived using live SARS-CoV-2. In a study of sera from over 100 convalescent patients, the pseudotype assay results were closely correlated with titers determined in a live virus neutralization assay (Noval et al., 2020) . 

A feature of soluble receptors is that because the virus spike protein needs to conserve its receptor binding affinity, they should maintain their ability to neutralize spike protein variants. SARS-CoV-2 S variants have been found to circulate in the human population and it is likely that others are yet to emerge, some of which may be less sensitive to neutralization by the therapeutic monoclonal antibodies currently under development. SARS-CoV-2 encoding the D614G spike protein has increased its frequency in the human population (Daniloski et al., 2020; Eaaswarkhanth et al., 2020; Korber et al., 2020) . The D614G spike protein was found to be more resistant to shedding from the virion, adopting a conformation that favors ACE2-binding and lowers the energy barrier to cell fusion (Daniloski et al., 2020; Ozono et al., 2020; . The ACE2 microbody maintained its ability to neutralize D614G spike protein-pseudotyped virus and was able to neutralize diverse β coronaviruses. The ACE2 microbody and similar soluble receptor proteins could be valuable tools able to neutralize coronaviruses that may be transferred to the human population in the future.

Such soluble receptor proteins could serve as off-the-shelf reagents that could be rapidly deployed.

We ACE2.293Tcells. The identity of the virus from which the spike protein RBD is derived is indicated above each histogram. Luciferase activity was measured after 2 days. The data are displayed as the mean ± SD and significance is determined by student-t tests.

The experiments in B and C were done three times and those in D and E were done twice. test. **** P<0.0001.

Resource Availability

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nathaniel R. Landau (nathaniel.landau@med.nyu.edu).

All unique DNA constructs, proteins and pseudotyped virus generated in this study are available from the Lead Contact upon request.

Additional supplemental items are available from Mendeley Data at http://dx.doi.org/10.17632/hsbn73xpkt.1.

K18-hACE2 mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J (McCray et al., 2007) ] were purchased from The Jackson Laboratory and bred in-house. Mice of both sexes between 6 and 8 weeks old were used for this study. SARS-CoV-2 stock was generated as previously described (Wei et al., 2020 The molecular masses of the purified protein complexes were determined by SEC/MALs. The proteins were injected onto a Superdex 200 10/300 GL gel-filtration chromatography column equilibrated in sample buffer connected to a Dawn Heleos II 18-angle light-scattering detector (Wyatt Technology), a dynamic light-scattering detector (DynaPro Nanostar; Wyatt Technology) and an Optilab t-rEX refractive index detector (Wyatt Technology). The data were collected at 25°C at a flow rate of 0.5 ml/minute every second. The molecular mass of each protein was determined by analysis with ASTRA 6 software.

Virion pull-down assay. Ratios were calculated as spike protein divided by P24 band intensities on an identical exposure of the blot.

Transfected cells were lysed in buffer containing 50 mM HEPES, 150 mM KCl, 2 mM EDTA, 0.5% NP-40, and protease inhibitor cocktail. Protein concentration in the lysates was measured by bicinchoninic protein assay and the lysates (40 µg) were separated by SDS-PAGE. The proteins were transferred to polyvinylidene difluoride membranes and probed with anti-HA mAb (Covance), mouse anti-His mAb (Invitrogen) and anti-GAPDH mAb (Life Technologies) followed by goat anti-mouse HRP-conjugated second antibody J o u r n a l P r e -p r o o f (Sigma). The blots were visualized using luminescent substrate (Millipore) on iBright CL1000.

Soluble ACE2 proteins (10 µg) were mixed with 20 µl nickel beads for 1 hour at 4°C.

Unbound protein was removed by washing the beads with PBS. The beads were resuspended in PBS and mixed with 40 µl pseudotyped lentiviral virions. After 1 hour incubation at 4°C, the beads were washed with PBS and resuspended in reducing

Laemmli loading buffer and heated to 90°C. The eluted proteins were separated by SDS-PAGE and analyzed on an immunoblot probed with anti-p24 antibody (AG3.0) followed by goat anti-mouse HRP-conjugated second antibody.

Live SARS-CoV-2 neutralization assay.

mNeonGreen SARS-CoV-2 (Xie et al., 2020) was obtained from the World Reference Center for Emerging Viruses and Arboviruses at the University of Texas Medical Branch.

The virus was passaged once on Vero.E6 cells (ATCC CRL-1586), clarified by low-speed centrifugation, aliquoted, and stored at -80°C. The infectious virus titer was determined by plaque assay on Vero.E6 cells. Virus neutralization was determined as previously described (Xie et al., 2020) . ACE2.293T cells were seeded in a 96-well plate (1 X 10 4 /well). The next day, mNeonGreen SARS-CoV-2 (MOI = 0.5) was mixed 1:1 with serially 2-fold diluted soluble ACE2 protein in DMEM/2% FBS and incubated for 1 hour at 37°C. The virus:protein mixture was then added to the ACE2 cells and incubated for 24 J o u r n a l P r e -p r o o f hours at 37°C in 5% CO 2 . The cells were fixed with 4% paraformaldehyde, stained with DAPI and the green fluorescent cells were counted on a CellInsight CX5 Platform high content microscope (Thermo Fisher).

All experiments were performed in technical duplicates or triplicates and data were analyzed using GraphPad Prism (Version 7 7.0e). Statistical significance was determined by the two-tailed, unpaired t test. Significance was based on two-sided testing and attributed to p< 0.05. Confidence intervals are shown as the mean ± SD or SEM. (*P≤ 0.05, **P≤ 0.01, ***P≤0.001, ****P≤0.0001). 

Mechanisms of coronavirus cell entry mediated by the viral spike protein

A versatile viral system for expression and depletion of proteins in mammalian cells

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants

Protocol and Reagents for

Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

The D614G mutation in SARS-CoV

Spike increases transduction of multiple human cell types. bioRxiv

Uses CD4 to Infect T Helper Lymphocytes. medRxiv

Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

Coronaviruses: an overview of their replication and pathogenesis

Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein

Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

A novel coronavirus associated with severe acute respiratory syndrome

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Functional assessment of cell entry and receptor usage for lineage B beta-coronaviruses

Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection

Receptor recognition mechanisms of coronaviruses: a decade of structural studies

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Insights from the association of SARS-CoV S-protein with its receptor, ACE2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Anti-retroviral activity of TRIM5 alpha

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization. bioRxiv

Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry. bioRxiv

UCSF Chimera--a visualization system for exploratory research and analysis

Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic

Angiotensin-I-converting enzyme and its relatives

Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Cell entry mechanisms of SARS-CoV-2

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies

Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease

Quantification of Reverse Transcriptase Activity by Real-Time PCR as a Fast and Accurate Method for Titration of HIV, Lenti-and Retroviral Vectors

Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

An Infectious cDNA Clone of SARS-CoV-2